Annual sales were KRW 48.5 billion in 2022, KRW 55.1 billion in 2023, KRW 59.7 billion in 2024 and KRW 65 billion in 2025, rising for three consecutive years from 2023 through 2025, with 2025 the largest year in the 2022–2025 span.
Operating profit moved from KRW 4.71 billion in 2022 to a peak of KRW 6.23 billion in 2023 (up 32.4% year on year), then fell to KRW 3.63 billion in 2024 (down 41.8%) and KRW 1.38 billion in 2025 (down 61.9%), declining for two consecutive years.
Operating margin went from 9.7% in 2022 to 11.3% in 2023, 6.1% in 2024 and 2.1% in 2025, so sales growth did not translate into margin improvement.
Net income attributable to controlling shareholders fell from KRW 5.56 billion in 2023 to KRW 3.84 billion in 2024 and KRW 2.59 billion in 2025, while net income including non-controlling interests was KRW 1.02 billion in 2025.
Daily Pharm attributed the 2025 profitability adjustment to overseas infrastructure expansion and system upgrade costs, along with the cost of consolidating subsidiaries.
The company cited the weaker domestic CRO market, delayed collection of receivables from some clients and heavier global investment as reasons for the margin decline, according to Money Today.
Operating cash flow went from KRW 2.52 billion in 2022, KRW 3.51 billion in 2023 and KRW 2.84 billion in 2024 to -KRW 3.07 billion in 2025. EBN reported that contract assets stood at KRW 21.4 billion at the end of 2025 and that short-term borrowings rose from KRW 705 million in 2024 to KRW 6.645 billion in 2025.
By quarter, sales were KRW 15.8 billion in Q3 2025, KRW 15.2 billion in Q4 2025 and KRW 14.8 billion in Q1 2026, then rose to KRW 17.8 billion in Q2 and KRW 19.3 billion in Q3 2026, increasing for two consecutive quarters.
Operating profit was KRW 246 million in Q3 2025 and KRW 92.64 million in Q4 2025, then turned to an operating loss of KRW 974 million in Q1 2026 before returning to a profit of KRW 176 million in Q2 and KRW 2.2 billion in Q3.
The Bio News reported that the company attributed the second-quarter turnaround to a recovery in the profitability of its core CRO business, while noting that R&D spending had partly limited consolidated profitability.
Net income attributable to controlling shareholders over the last four quarters, from Q4 2025 to Q3 2026, totaled KRW 2.98 billion.